Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;29(1):1-4.
doi: 10.1007/s40620-015-0245-6. Epub 2015 Nov 13.

Role of complement in IgA nephropathy

Mohamed R Daha  1 , Cees van Kooten  2
Affiliations
Review

Role of complement in IgA nephropathy

Mohamed R Daha et al. J Nephrol. 2016 Feb.

Abstract

Immunoglobulin A nephropathy (IgAN) is characterized by the deposition of IgA in the mesangium of glomeruli. This mesangial IgA has been found to consist mainly of polymeric IgA1 which drives the activation of the mesangial cells and results in excessive production of several inflammatory mediators. The activation of mesangial cells is amplified by the ability of IgA to activate the complement system, originally thought to occur mainly via the alternative pathway of complement. However more recent studies indicate that lectin pathway involvement has a strong association with progression of renal disease. In this review we summarize the contribution of complement to the IgA- mediated inflammatory process.

Keywords: C4d; Complement; IgA nephropathy; MBL.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Complement in IgAN. Schematic view how deposition of high MW IgA deposited in the mesangial area of the kidney can activate the complement system through either the lectin or the alternative pathway. This will amplify the local inflammatory response and contribute to renal injury and loss of function. AP alternative pathway, LP lectin pathway, CP classical pathway, MW molecular weight, IgA immunoglobulin A
See this image and copyright information in PMC

References

    1. Garred P, Honore C, Ma YJ, Munthe-Fog L, Hummelshoj T. MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Mol Immunol. 2009;46(14):2737–2744. doi: 10.1016/j.molimm.2009.05.005. - DOI - PubMed
    1. Gorsuch WB, Chrysanthou E, Schwaeble WJ, Stahl GL. The complement system in ischemia-reperfusion injuries. Immunobiology. 2012;217(11):1026–1033. doi: 10.1016/j.imbio.2012.07.024. - DOI - PMC - PubMed
    1. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 1996;271:348–350. doi: 10.1126/science.271.5247.348. - DOI - PubMed
    1. Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol. 2010;28:131–155. doi: 10.1146/annurev-immunol-030409-101250. - DOI - PubMed
    1. Nauta AJ, Daha MR, van Kooten C, Roos A. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol. 2003;24:148–154. doi: 10.1016/S1471-4906(03)00030-9. - DOI - PubMed

MeSH terms

Substances